Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients: 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin

European Journal of Cancer

Volumn 39, Issue 8, 2003, Pages 1129-1140

  Dittrich, Ch ^a   Sevelda, P ^b   Salzer, H ^c   Obermair, A ^d   Speiser, P ^d   Breitenecker, G ^d   Schemper, M ^d   Kaider, A ^d  

^a KAISER FRANZ JOSEF HOSPITAL   (Austria)

^b GENERAL HOSPITAL LINZ   (Austria)

^c WILHELMINEN HOSPITAL   (Austria)

^d UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cisplatin carboplatin combination therapy; Ovarian cancer; Phase III study; Platinum dose intensity; Randomised trial

Indexed keywords

CARBOPLATIN; CISPLATIN; CREATININE; CYCLOPHOSPHAMIDE; PLATINUM;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE CALCULATION; DOSE RESPONSE; DRUG INTERMITTENT THERAPY; FOLLOW UP; GRANULOCYTOPENIA; HUMAN; HUMAN TISSUE; INFECTION; KIDNEY DISEASE; LEUKOPENIA; MAJOR CLINICAL STUDY; MORBIDITY; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; OVARY CARCINOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0038740860     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00152-7     Document Type: Article

References (27)

1. Neijt J.P., ten Bokkel Huinink W.W., van der Burg M.E.et al. Randomised trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J. Clin. Oncol. 5:1987;1157-1168.
2. Bertelsen K., Jakobsen A., Andersen J.E.et al. A randomised study of cyclophosphamide and cis-platinum with and without doxorubicin in advanced ovarian carcinoma. Gynecol. Oncol. 28:1987;161-169.
3. Omura G.A., Bundy B.N., Berek J.S., Curry S., Delgado G., Mortel R. Randomised trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma. a Gynecologic Oncology Group Study J. Clin. Oncol. 7:1989;457-465.
4. Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Lancet. 2:1987;353-359.
5. Dittrich C. Ovarialkarzinom. Dittrich Ch. Angewandte Onkologie. 1989;80-165 Springer-Verlag, Wien, New York.
6. Neijt J.P., ten Bokkel Huinink W.W., van der Burg M.E., van Oosterom A.T. Complete remission at laparotomy. still a gold standard in ovarian cancer? Lancet. 1:1986;1028.
7. Dittrich C. Klonieren von soliden Tumoren. Therapiesimulation, Therapieoptimierung und Prognoseerstellung am Beispiel des Ovarialkarzinoms. 1987;Springer-Verlag, Wien, New York.
8. Wiltshaw E., Subramarian S., Alexopoulos C., Barker G.H. Cancer of the ovary. a summary of experience with cis-dichlorodiammineplatinum (II) at the Royal Marsden Hospital Cancer Treat. Rep. 63:1979;1545-1548.
9. Ozols R.F., Corden B.J., Jacob J., Wesley M.N., Ostchega Y., Young R.C. High-dose cisplatin in hypertonic saline. Ann. Intern. Med. 100:1984;19-24.
10. Levin L., Hryniuk W.M. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J. Clin. Oncol. 5:1987;756-767.
11. Ozols R.F. Cisplatin dose intensity. Semin. Oncol. 16(Suppl. 6):1989;22-30.
12. Mangioni C., Bolis G., Pecorelli S.et al. Randomised trial in advanced ovarian cancer comparing cisplatin and carboplatin. J. Natl. Cancer Inst. 81:1989;1464-1471.
13. Piccart M.J., Nogaret J.M., Marcelis L.et al. Cisplatin combined with carboplatin. a new way of intensification of platinum dose in the treatment of advanced ovarian cancer J. Natl. Cancer Inst. 82:1990;703-707.
14. Lund B., Hansen M., Hansen O.P., Hansen H.H. High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease. J. Clin. Oncol. 7:1989;1469-1473.
15. Dittrich C., Sevelda P., Baur M.et al. In vitro and in vivo evaluation of the combination of cisplatin and its analogue carboplatin for platinum dose intensification in ovarian carcinoma. Cancer. 71:1993;3082-3090.
16. Changes in definitions of clinical staging for carcinoma of the cervix and ovary. Am. J. Obstet. Gynecol. 156:1987;263-264.
17. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
18. Stplan. Calculations for Sample Size and Related Problems, Version 20, Houston, USA, Department of Biomathematics, The University of Texas MDACC, 1987.
19. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 50:1966;163-170.
20. Pocock S.J., Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 31:1975;103-115.
21. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Statist. Assoc. 53:1958;457-481.
22. Cox D.R. Regression models and life-tables. J. R. Statist Soc. B. 34:1972;187-220.
23. Schemper M., Smith T.L. A note on quantifying follow-up in studies of failure time. Control Clin. Trials. 17:1996;343-346.
24. Greco F.A., Julian C.G., Richardson R.L., Burnett L., Hande K.R., Oldham R.K. Advanced ovarian cancer. brief intensive combination chemotherapy and second-look operation Obstet. Gynecol. 58:1981;199-205.
25. McGuire W.P., Hoskins W.J., Brady M.F.et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer. a Gynecologic Oncology Group Study J. Clin. Oncol. 13:1995;1589-1599.
26. Hoskins W.J., McGuire W.P., Brady M.F.et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obstet. Gynecol. 170:1994;974-979.
27. Begg C., Cho M., Eastwood S.et al. Improving the quality of reporting of randomised controlled trials: the CONSORT statement. JAMA. 276:1996;637-639.